CD133+ cells

Phase 1Biologic

RRoyan Institute

CD133+ cells is one of 18 biologic programs targeting Osteonecrosis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteonecrosisActive, not recruiting

OsteonecrosisPhase 1

Active, not recruiting

Competition

Competitive Landscape

31 competitors in Osteonecrosis

#DrugCompanyPhaseTrials

Fosamax

OOrganon and Co

Approved

2 2

Bayer Aspirin

Bayer

Phase 3

1 3

Antibiotics

MMelinta Therapeutics, Inc.

Approved

1 4

Trental

VValidus Pharmaceuticals

Phase 3

1 5

Boniva

CConrado Roberto Hoffmann Filho

Phase 3

1 6

Zometa

Pfizer

Phase 2

5 7

Aquasol E

NNational Eye Institute (NEI)

Phase 3

—8

Tocopherol

MM.D. Anderson Cancer Center

Phase 3

1 9

Ixmyelocel-T

VVericel Corporation

Phase 3

1 10

Ibandronate IV

NNational Taiwan University Hospital

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Osteonecrosis1 trial

Evaluate the Effect of Bone Marrow Derived Cd133+ Cells in Patient With Osteonecrosis of Femoral Head

Completed·RRoyan Institute·Phase 1·NCT01198080·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CD133+ cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CD133+ cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CD133+ cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Royan Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: RRoyan Institute

CD133+ cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Osteonecrosis1 trial

References

Drug Info

Quick Facts

Related News